Medical Condition News

RSS

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Cubist Pharmaceuticals, Inc. today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.

15 May 2012

Five new capabilities added to Aetna Rx Check Program

Aetna today announced that it is adding five new capabilities to Aetna Rx Check, a collection of programs designed to promote safety and prevent the misuse of various prescription drugs such as pain medications and antibiotics.

15 May 2012

Researchers identify new biomarker and therapeutic target for pancreatic cancer

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.

15 May 2012

Latest statistics: Cancer deaths in 50-59 year olds have dropped to 14,000

The number of people in their 50s dying prematurely from cancer in the UK has fallen below 14,000 for the first time in 40 years according to new Cancer Research UK figures published today.

15 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.

15 May 2012

Celleration initiates enrollment in MIST Therapy study for VLU

Celleration, Inc., a privately-held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announced the first patient enrollment in IN-BALANCE VLU (Inflammation, Bacteria, & Angiogenesis effects in Launching Venous Leg Ulcer healing: A Clinical Evaluation).

15 May 2012

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

Latest research on caring for ischemic stroke patients

Following a stroke, factors as varied as blood sugar, body temperature and position in bed can affect patient outcomes, Loyola University Medical Center researchers report.

15 May 2012

BioAlliance Pharma commences Livatag phase III trial in hepatocellular carcinoma

BioAlliance Pharma SA, a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag(doxorubicin Transdrug), as scheduled in the advancement calendar of the project.

15 May 2012

Cockroaches can trigger allergy and asthma attacks

In recognition of National Asthma and Allergy Awareness Month, celebrated in May, the National Pest Management Association (NPMA) is reminding people that cockroaches can trigger asthma and allergy attacks, along with other pertinent diseases.

15 May 2012

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Eli Lilly and Company will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.

15 May 2012

Fibrocell submits azficel-T Phase II study protocol with FDA to treat restrictive burn scars

Fibrocell Science, Inc. announced today that is has submitted to the U.S. Food & Drug Administration (FDA) the company's Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell's lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn scars.

15 May 2012

Study identifies how skeletal muscle stem cells respond to muscle injury

A study conducted by Children's Hospital & Research Center Oakland scientists identifies how skeletal muscle stem cells respond to muscle injury and may be stimulated to improve muscle repair in Duchenne Muscular Dystrophy, a severe inherited disease of muscle that causes weakness, disability and, ultimately, heart and respiratory failure.

15 May 2012

MicroRNA-3151 a new independent prognostic marker for acute leukemia

A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes.

15 May 2012

Acupuncture may improve dyspnea in COPD patients

According to a small clinical trial reported by investigators from Japan, acupuncture appears to be associated with improvement of dyspnea (labored breathing) on exertion, in patients with chronic obstructive pulmonary disease (COPD), according to a study published Online First by Archives of Internal Medicine, a JAMA Network publication.

14 May 2012

Feeding tubes may make sores more likely to develop in dementia patients

A new study led by Brown University researchers reports that percutaneous endoscopic gastric (PEG) feeding tubes, long assumed to help bedridden dementia patients stave off or overcome pressure ulcers, may instead make the horrible sores more likely to develop or not improve.

14 May 2012

First U.S. outpatient trial of UVA-developed artificial pancreas

The University of Virginia School of Medicine has launched the first U.S. outpatient trial of a UVA-developed artificial pancreas that could make it easier for type 1 diabetes patients to manage their condition.

14 May 2012

FDA clears Bioness smaller leg cuff for use with L300 Foot Drop System

Bioness Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a smaller leg cuff for use with the company's L300 Foot Drop System.

14 May 2012

Groundbreaking biohybrid device to control acute inflammation to prevent sepsis

The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology.

14 May 2012